Loading...
Symbols:
Loading...
Symbols:
Introgen Therapeutics, Inc. (INGN)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Introgen Therapeutics, Inc. (INGN)
16 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on INGN
Most popular authors
(tracked in watchlists)
- Alan Brochstein(132)
- Mike Havrilla(105)
- ChinaBio Today(61)
- 10Q Detective(14)
- SA Editor Judith Levy(6)
Most commented on authors
- Alan Brochstein(8)
- The Biotech Onion (6)
- Centient Biotech Investor(0)
- PharmaTracker (0)
- Kevin McNamara(0)
- FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen
- Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile
- Cancer Stocks: Tracking the Market
- Introgen Hints At Cancer Gene Therapy Lawsuit Against Benda
- Cancer Stocks Slide Again
- Cancer Stocks Plunge Following ASCO Meeting
- Cancer Stocks Soar With Annual ASCO Meeting
- Cancer Stocks on the Go: Winners and Losers
- Introgen Therapeutics: Empty Promises For Cancer Patients and Shareholders
- Introgen Reports Positive Result in FUS1 Clinical Trial
- Why Introgen is a Terminal Case
- Unanswered Questions Support a Short Position in Introgen
- Introgen: Setting The Record Straight On Its Biomarker Claims
- Why Keeping Money in Introgen is a Fool's Game
- Biotech Stocks Day In Review: Will Sanofi-Aventis Merge With Bristol-Myers Squibb?
- Biotech Stocks Day-in-Review: Genentech Beats Estimates
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »